Hypoplastic Left Heart Syndrome: Expression of RHD in the Fetus?

左心发育不全综合征:RHD 在胎儿中的表达?

基本信息

  • 批准号:
    8256360
  • 负责人:
  • 金额:
    $ 30.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-01-15 至 2014-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Hypoplastic Left Heart Syndrome (HLHS) is a severe and devastating heart defect that affects ~ 1 in 10,000 children born each year. The mechanism(s) leading to pathogenesis of HLHS and associated left-sided cardiac pathology remain unknown. The goal of this proposal is to test a novel hypothesis that states HLHS is an expression of rheumatic heart disease (RHD) in the fetus. In RHD, among other immunologic processes, anti-streptococcal antibodies are generated in response to strep infection. In genetically susceptible hosts these antibodies then "cross-react" with left-sided myocardial and valvular antigens through a mechanism known as molecular mimicry. We propose similar mechanism for the pathogenesis of HLHS in which maternal antibodies produced in response to antecedent (and recurrent) strep infection, cross the placenta and damage the fetal heart in the susceptible host. Our preliminary data suggest not only a strong association between HLHS and prior maternal strep infection, but also elevated anti-human cardiac myosin serum titers in mothers of HLHS babies (as found in patients with rheumatic fever), compared with three control groups. To extend these studies, we will compare groups of pregnant women referred for fetal echocardiography (echo) and found to have a pregnancy affected by (1) HLHS; (2) congenital heart disease other than HLHS; and (3) nothing (i.e., normal fetal echo, "referred" controls). A fourth group ("random" controls) are recruited from the general population early in pregnancy (<18 weeks) to overcome the obvious selection biases in the "referred" controls. In Aim 1 we determine if mothers of babies with HLHS have a significant history of strep infections through a questionnaire tool, review of maternal medical records and measurements of blood titers of an anti-streptococcal antibody (ASO). In Aim 2, using serum from the repository of samples obtained from the 4 groups of subjects in Aim 1, we will also compare antibody reactivity with a variety of valvular/myocardial antigens (shown to be involved in RHD lesions); these are then compared to matched serum samples obtained from the babies after birth. In Aim 3, we determine if heart reactive antibodies and inflammatory markers (TNF-alpha, INF-gamma and IL-4) implicated in valvular lesions in RHD are also present in myocardial tissue specimens obtained from HLHS babies (at the time of neonatal surgical intervention). Immunohistochemical analysis of neonatal heart tissues will be performed to assess for the presence of immunoglobulin deposition and other immune markers. The candidate: Dr. Eghtesady is a pediatric cardiothoracic surgeon who has had long standing interest in the pathogenesis of HLHS and its medical/surgical management. Pertaining to the proposed studies, his long-term career goal is to improve the quality of life for the children and families affected by this severe and devastating ongenital heart disease. The research environment: CCHMC and The Heart Institute (THI) of CCHMC are dedicated to improve child health and transform delivery of care through fully integrated, globally recognized research, education and innovation. The mission of CCHMC is to achieve the best medical and quality of life outcomes, patient and family experiences and value, for patients from the community, the nation and the world. For this reason, the success of studies such as proposed is of high priority to CCHMC and the HI. Significant resources are provided for this purpose with great commitment to ensure a thriving environment that allows for extensive collaborative arrangements, as in this study. Dr Eghtesady's clinical schedule has been structured to afford him 50% protected time for research. In 2007, CCHMC was awarded full accreditation by the Association for the Accreditation of Human Research Protection Programs confirming the strength and commitment to clinical research programs. Finally, in 2008, the HI Clinical Research Core was established to specifically see through the success of ongoing clinical studies, through rigorous oversight and provision of additional resources. Relevance: Each year, 1 out of 100 children born is affected by a congenital heart disease. Among these, HLHS is perhaps the most severe and devastating, significantly impacting the lives of affected families. Tremendous resources are devoted to its medical management. Therefore, understanding why HLHS happens, the goal of the proposed research would have great significance and relevance to public health. PUBLIC HEALTH RELEVANCE: The proposed project has the potential to improve public health by preventing and/or defining alternative treatments for babies with Hypoplastic Left Heart Syndrome (HLHS), a devastating congenital heart defect. We propose to test a novel theory that there is a potential association between pharyngeal streptococcal infection or "strep throat" in mothers and the development of HLHS in their babies. If proven true, the findings will have a profound impact on this disease and the lives of many mothers and their affected babies.
描述(由申请人提供):左心发育不全综合征(HLHS)是一种严重的、毁灭性的心脏缺陷,每年出生的儿童中约有1 / 10,000。导致HLHS发病和相关左心病理的机制尚不清楚。这项提议的目的是验证一个新的假设,即HLHS是胎儿风湿性心脏病(RHD)的一种表达。在RHD中,在其他免疫过程中,抗链球菌抗体是在对链球菌感染的反应中产生的。在基因易感的宿主体内,这些抗体随后通过一种被称为分子模仿的机制与左侧心肌和瓣膜抗原“交叉反应”。我们提出了类似的HLHS发病机制,即母体抗体对先前(和复发)链球菌感染的反应,穿过胎盘,损害易感宿主的胎儿心脏。我们的初步数据表明,与三个对照组相比,HLHS婴儿的母亲(如风湿热患者)的抗人心肌肌球蛋白血清滴度升高,不仅HLHS与母亲先前的链球菌感染有很强的相关性,而且HLHS婴儿的母亲(如风湿热患者)的抗人心肌肌球蛋白血清滴度升高。为了扩展这些研究,我们将比较两组孕妇进行胎儿超声心动图(echo)检查,发现妊娠受以下因素影响:(1)HLHS;(二)先天性心脏病以外的其他疾病;(3)什么都没有(即正常胎儿回声,“参照”对照)。第四组(“随机”对照)是从怀孕早期(<18周)的普通人群中招募的,以克服“参考”对照中明显的选择偏差。在目的1中,我们通过问卷调查工具,回顾母亲的医疗记录和测量抗链球菌抗体(ASO)的血液滴度来确定患有HLHS婴儿的母亲是否有明显的链球菌感染史。在第二项研究中,使用从第一项研究中四组受试者的样本库中获得的血清,我们还将比较抗体与各种瓣膜/心肌抗原(显示与RHD病变有关)的反应性;然后将这些样本与出生后从婴儿身上获得的匹配血清样本进行比较。在Aim 3中,我们确定与RHD瓣膜病变相关的心脏反应性抗体和炎症标志物(tnf - α, nf - γ和IL-4)是否也存在于从HLHS婴儿(在新生儿手术干预时)获得的心肌组织标本中。将对新生儿心脏组织进行免疫组织化学分析,以评估免疫球蛋白沉积和其他免疫标志物的存在。候选人:Eghtesady博士是一名儿科心胸外科医生,长期以来一直对HLHS的发病机制及其医学/外科治疗感兴趣。关于拟议的研究,他的长期职业目标是改善受这种严重和毁灭性的生殖器官心脏病影响的儿童和家庭的生活质量。研究环境:CCHMC和CCHMC的心脏研究所(THI)致力于通过全面整合,全球公认的研究,教育和创新来改善儿童健康和改变护理方式。CCHMC的使命是为来自社区、国家和世界的患者实现最佳的医疗和生活质量结果、患者和家庭体验和价值。因此,研究的成功是CCHMC和HI的首要任务。为此目的提供了大量资源,并承诺确保一个繁荣的环境,允许广泛的合作安排,就像本研究一样。Eghtesady博士的临床安排为他提供了50%的研究保护时间。2007年,CCHMC获得了人类研究保护项目认证协会的全面认证,确认了临床研究项目的实力和承诺。最后,在2008年,建立了HI临床研究核心,专门通过严格的监督和提供额外的资源,确保正在进行的临床研究取得成功。相关性:每年每100个新生儿中就有1个患有先天性心脏病。其中,HLHS可能是最严重和最具破坏性的,严重影响受影响家庭的生活。其医疗管理投入了大量资源。因此,了解HLHS发生的原因,提出的研究目标将对公共卫生具有重要意义和相关性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Pirooz Eghtesady其他文献

Pirooz Eghtesady的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Pirooz Eghtesady', 18)}}的其他基金

Developing an animal model of HLHS: role of immune mediated injury
建立 HLHS 动物模型:免疫介导损伤的作用
  • 批准号:
    8305512
  • 财政年份:
    2011
  • 资助金额:
    $ 30.75万
  • 项目类别:
Developing an animal model of HLHS: role of immune mediated injury
建立 HLHS 动物模型:免疫介导损伤的作用
  • 批准号:
    8190837
  • 财政年份:
    2011
  • 资助金额:
    $ 30.75万
  • 项目类别:
Hypoplastic Left Heart Syndrome: Expression of RHD in the Fetus?
左心发育不全综合征:RHD 在胎儿中的表达?
  • 批准号:
    8206786
  • 财政年份:
    2010
  • 资助金额:
    $ 30.75万
  • 项目类别:
Hypoplastic Left Heart Syndrome: Expression of RHD in the Fetus?
左心发育不全综合征:RHD 在胎儿中的表达?
  • 批准号:
    7771616
  • 财政年份:
    2010
  • 资助金额:
    $ 30.75万
  • 项目类别:
Hypoplastic Left Heart Syndrome: Expression of RHD in the Fetus?
左心发育不全综合征:RHD 在胎儿中的表达?
  • 批准号:
    8399055
  • 财政年份:
    2010
  • 资助金额:
    $ 30.75万
  • 项目类别:
Hypoplastic Left Heart Syndrome: Expression of RHD in the Fetus?
左心发育不全综合征:RHD 在胎儿中的表达?
  • 批准号:
    8011422
  • 财政年份:
    2010
  • 资助金额:
    $ 30.75万
  • 项目类别:
Mechanism of Vasopressin-Mediated Placental Vascular Resistance after Fetal Bypas
胎儿绕道术后加压素介导的胎盘血管阻力机制
  • 批准号:
    7780332
  • 财政年份:
    2009
  • 资助金额:
    $ 30.75万
  • 项目类别:
Mechanism of Vasopressin-Mediated Placental Vascular Resistance after Fetal Bypas
胎儿绕道术后加压素介导的胎盘血管阻力机制
  • 批准号:
    7660599
  • 财政年份:
    2009
  • 资助金额:
    $ 30.75万
  • 项目类别:
Mechanism of Vasopressin-Mediated Placental Vascular Resistance after Fetal Bypas
胎儿绕道术后加压素介导的胎盘血管阻力机制
  • 批准号:
    7836995
  • 财政年份:
    2009
  • 资助金额:
    $ 30.75万
  • 项目类别:

相似海外基金

Chimella application for Sap points accreditation
Chimella 申请 Sap 积分认证
  • 批准号:
    10106576
  • 财政年份:
    2024
  • 资助金额:
    $ 30.75万
  • 项目类别:
    Collaborative R&D
heata - SAP Accreditation Stage 5b
heata - SAP 认证阶段 5b
  • 批准号:
    10104998
  • 财政年份:
    2024
  • 资助金额:
    $ 30.75万
  • 项目类别:
    Collaborative R&D
Accreditation for Analogue Quantum Computing Systems
模拟量子计算系统认证
  • 批准号:
    2741223
  • 财政年份:
    2022
  • 资助金额:
    $ 30.75万
  • 项目类别:
    Studentship
Harnessing heat from compute: SAP Accreditation
利用计算的热量:SAP 认证
  • 批准号:
    10017625
  • 财政年份:
    2022
  • 资助金额:
    $ 30.75万
  • 项目类别:
    Collaborative R&D
Comparative Inquiry of Teacher Accreditation Requirements
教师认证要求的比较查询
  • 批准号:
    17K04553
  • 财政年份:
    2021
  • 资助金额:
    $ 30.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Comparison of AAVLD Laboratory Accreditation Requirements V 2021.01 with ISO17025:2017
AAVLD 实验室认可要求 V 2021.01 与 ISO17025:2017 的比较
  • 批准号:
    10215868
  • 财政年份:
    2020
  • 资助金额:
    $ 30.75万
  • 项目类别:
Expansion of Pennsylvania's State Food and Feed Laboratory Services in Response to the 2011 Food Safety Modernization Act, Laboratory Accreditation Rule, and the FDA Integrated Food Safety System
为响应 2011 年食品安全现代化法案、实验室认可规则和 FDA 综合食品安全系统,扩大宾夕法尼亚州食品和饲料实验室服务
  • 批准号:
    10176002
  • 财政年份:
    2020
  • 资助金额:
    $ 30.75万
  • 项目类别:
Expansion of Pennsylvania's State Food and Feed Laboratory Services in Response to the 2011 Food Safety Modernization Act, Laboratory Accreditation Rule, and the FDA Integrated Food Safety System
为响应 2011 年食品安全现代化法案、实验室认可规则和 FDA 综合食品安全系统,扩大宾夕法尼亚州食品和饲料实验室服务
  • 批准号:
    10256693
  • 财政年份:
    2020
  • 资助金额:
    $ 30.75万
  • 项目类别:
Expansion of Pennsylvania's State Food and Feed Laboratory Services in Response to the 2011 Food Safety Modernization Act, Laboratory Accreditation Rule, and the FDA Integrated Food Safety System
为响应 2011 年食品安全现代化法案、实验室认可规则和 FDA 综合食品安全系统,扩大宾夕法尼亚州食品和饲料实验室服务
  • 批准号:
    10447639
  • 财政年份:
    2020
  • 资助金额:
    $ 30.75万
  • 项目类别:
Expansion of Pennsylvania's State Food and Feed Laboratory Services in Response to the 2011 Food Safety Modernization Act, Laboratory Accreditation Rule, and the FDA Integrated Food Safety System
为响应 2011 年食品安全现代化法案、实验室认可规则和 FDA 综合食品安全系统,扩大宾夕法尼亚州食品和饲料实验室服务
  • 批准号:
    10675467
  • 财政年份:
    2020
  • 资助金额:
    $ 30.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了